Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has maintained a Neutral rating on Tandem Diabetes Care (NASDAQ:TNDM) and increased the price target from $25 to $31.

March 15, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has maintained a Neutral rating on Tandem Diabetes Care but raised the price target from $25 to $31.
The increase in price target by Citigroup, despite maintaining a Neutral rating, suggests an improved outlook for Tandem Diabetes Care's stock. This adjustment reflects a positive sentiment towards the company's future performance and could lead to increased investor interest, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100